Results 171 to 180 of about 12,413,959 (307)

Proteomic and Ubiquitinated Proteome Insights Into ER Stress Responses in Chinese Hamster Ovary Cells Under Mild Hypothermic Conditions

Biotechnology and Bioengineering, Volume 123, Issue 1, Page 5-25, January 2026.
Proteomic analysis of CHO cells under mild hypothermia (31°C) reveals ER stress responses, ubiquitination dynamics, and adaptive mechanisms. Magnetic immuno‐affinity enrichment and mass spectrometry highlight protein regulation differences in non‐producer versus producer cells, offering insights for optimising biopharmaceutical production of IgG1 and ...
David Ryan, Christiana‐Kondylo Sideri, Michael Henry, Selvaprakash Karuppuchamy, Esen Efeoglu, Paula Meleady   +5 more
wiley   +1 more source

Haemophilia B: an illustrative review of current challenges and opportunities. [PDF]

Res Pract Thromb Haemost
Hermans C, Astermark J, Trakymienė SŠ, Jiménez-Yuste V.   +3 more
europepmc   +1 more source

Continuous infusion factor replacement in haemophilia B during and after cardiac surgery: the better choice? [PDF]

BMJ Case Rep, 2020
Farid S, Sewaralthahab S, Smith HP.
europepmc   +1 more source

Haemophilia A and B – evaluation of the Swedish prophylactic regimen by magnetic resonance imaging

, 2022
Björn Lundin, Fariba Baghaei, Margareta Holmström, Pia Petrini, Gunilla Müller, Sven Månsson, Rolf Ljung   +6 more
openalex   +1 more source

Downstream Process Intensification for AAV Purification by Affinity Chromatography Using Single Pass Tangential Flow Filtration

Biotechnology and Bioengineering, Volume 123, Issue 1, Page 174-185, January 2026.
ABSTRACT To enable adeno‐associated viral vectors (AAV) to achieve their maximum potential, next‐generation manufacturing processes must be developed to make gene therapies more affordable and accessible. This study focused on the design of two different intensified AAV downstream manufacturing processes at bench and pilot scale.
Akshay S. Chaubal, Ronny Horax, Christopher J. Yehl, S. Ranil Wickramasinghe, Xianghong Qian, Lu Wang, Andrew L. Zydney   +6 more
wiley   +1 more source

Real-World Use of Extended Half-Life Factor IX in Children with Haemophilia B. [PDF]

Life (Basel)
Dettoraki A, Michalopoulou A, Saslis S, Dakou K, Stamati I, Thymianou S, Kapsimali Z, Papakonstantinou O, Pergantou H.   +8 more
europepmc   +1 more source

Benign endobronchial lesion causing massive haemoptysis in a patient with haemophilia B. [PDF]

BMJ Case Rep, 2020
Mosalem O, Abu Rous F, Abro C, Kherallah S.   +3 more
europepmc   +1 more source

Interfacility Collaboration for Hemophilia Care in Japan: A Retrospective Database Study Using a Japanese Healthcare Claims Database

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims In Japan, about 6000 patients with hemophilia A (PwHA) are separately cared for at ~1000 clinics or hospitals. Interfacility collaboration (IFC) between hemophilia treatment centers and “satellite” medical facilities located closer to patients is necessary to eliminate care disparities.
Ei Kinai, Masako Yamaguchi, Akira Shirahata   +2 more
wiley   +1 more source

Vitamin K deficiency bleeding of newborn masquerading haemophilia B. [PDF]

Sudan J Paediatr, 2020
Kumar M, Kumar S, Bajpayi S, Kumari R.
europepmc   +1 more source

Rebalancing Hemostasis: Fitusiran as a First‐in‐Class RNAi Therapy in Hemophilia A and B

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Fitusiran is a first‐in‐class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor‐independent prophylaxis.
Raza Ur Rehman, Rida Fatima, Aymar Akilimali   +2 more
wiley   +1 more source